{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:51Z","timestamp":1793060031288,"version":"4.5.0"},"reference-count":43,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate tocilizumab (TCZ) efficacy in patients with refractory Beh\u00e7et disease (BD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a multicenter study of 30 patients fulfilling the international criteria for BD and treated with TCZ at different European referral centers. The clinical response was evaluated at 6 months from TCZ initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety percent of patients with BD were refractory or intolerant to anti\u2013tumor necrosis factor (anti-TNF) agents. Overall, TCZ was effective in 25 (83%) patients with BD of whom 18 (60%) and 7 (23%) were complete and partial responders, respectively. The complete response was 67%, 60%, and 42% in patients with uveitis (18\/30), neurological manifestations (5\/30), and mucocutaneous and\/or articular (7\/30) manifestations, respectively. TCZ had a significant steroid-sparing effect allowing patients to decrease their median daily prednisone dose from 20 (IQR 10-40) mg\/day to 9 (IQR 5-13) mg at 6 months (<jats:italic>P<\/jats:italic>&lt; 0.001). The number of patients with BD needing concomitant disease-modifying antirheumatic drug therapy fell from 7 (23%) to 4 (13%) at 6 months. Mild to moderate side effects were observed in 6 (20%) patients, and 3 (10%) presented with serious adverse events (pneumonia, intestinal perforation, and septicemia) requiring therapy discontinuation in 2 cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TCZ seems to be an effective alternative to anti-TNF agents in treating BD-related uveitis and neurological manifestations.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.221106","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T09:06:44Z","timestamp":1679044004000},"page":"916-923","source":"Crossref","is-referenced-by-count":30,"title":["Tocilizumab in Beh\u00e7et Disease: A Multicenter Study of 30 Patients"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-5750","authenticated-orcid":false,"given":"Mohamed-Yacine","family":"Khitri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Deroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3117","authenticated-orcid":false,"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-0163","authenticated-orcid":false,"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"2023080910450959000_50.7.916.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"},{"key":"2023080910450959000_50.7.916.2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","article-title":"Behcet\u2019s disease: epidemiology, clinical manifestations, and diagnosis","volume":"13","author":"Davatchi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2023080910450959000_50.7.916.3","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease. International Study Group for Beh\u00e7et\u2019s Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"2023080910450959000_50.7.916.4","doi-asserted-by":"crossref","first-page":"iii101","DOI":"10.1093\/rheumatology\/kez626","article-title":"Beh\u00e7et: the syndrome","volume":"59","author":"Bettiol","year":"2020","journal-title":"Rheumatol"},{"key":"2023080910450959000_50.7.916.5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","article-title":"Phenotypes in Beh\u00e7et\u2019s syndrome","volume":"14","author":"Seyahi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2023080910450959000_50.7.916.6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-021-01011-z","article-title":"Advances in the treatment of Behcet\u2019s disease","volume":"23","author":"Alibaz-Oner","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2023080910450959000_50.7.916.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225"},{"key":"2023080910450959000_50.7.916.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"2023080910450959000_50.7.916.9","doi-asserted-by":"crossref","first-page":"624795","DOI":"10.3389\/fmed.2021.624795","article-title":"Treatment of Beh\u00e7et\u2019s disease: an algorithmic multidisciplinary approach","volume":"8","author":"Alpsoy","year":"2021","journal-title":"Front Med"},{"key":"2023080910450959000_50.7.916.10","first-page":"S149","article-title":"Anti-cytokine biologic treatment beyond anti-TNF in Beh\u00e7et\u2019s disease","volume":"32","author":"Arida","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2023080910450959000_50.7.916.11","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long-term outcome of ustekinumab therapy for Beh\u00e7et\u2019s disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023080910450959000_50.7.916.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217108"},{"key":"2023080910450959000_50.7.916.13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1684\/ecn.2019.0421","article-title":"IL-17, IL-10, IL-6, and IFN-\u03b3 in Egyptian Beh\u00e7et\u2019s disease: correlation with clinical manifestations","volume":"30","author":"Talaat","year":"2019","journal-title":"Eur Cytokine Netw"},{"key":"2023080910450959000_50.7.916.14","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.4268"},{"key":"2023080910450959000_50.7.916.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken489"},{"key":"2023080910450959000_50.7.916.16","first-page":"393","article-title":"[The changes of Th lymphocyte subsets in patients with Behcet disease]. [Article in Chinese]","volume":"47","author":"Liang","year":"2011","journal-title":"Zhonghua yan ke za zhi"},{"key":"2023080910450959000_50.7.916.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2011.10.024"},{"key":"2023080910450959000_50.7.916.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0497-5"},{"key":"2023080910450959000_50.7.916.19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2023080910450959000_50.7.916.20","first-page":"2057","article-title":"Tocilizumab in the treatment of severe and\/or refractory vasculo-Beh\u00e7et\u2019s disease: a single-centre experience in China","volume":"57","author":"Ding","year":"2018","journal-title":"Rheumatol"},{"key":"2023080910450959000_50.7.916.21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in Beh\u00e7et\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes","volume":"39","author":"Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2023080910450959000_50.7.916.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev255"},{"key":"2023080910450959000_50.7.916.23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.semarthrit.2016.03.006","article-title":"Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Beh\u00e7et\u2019s disease","volume":"46","author":"Emmi","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2023080910450959000_50.7.916.24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12107"},{"key":"2023080910450959000_50.7.916.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(85)34001-0"},{"key":"2023080910450959000_50.7.916.26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet\u2019s disease: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2023080910450959000_50.7.916.27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the treatment of Beh\u00e7et uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy","volume":"26","author":"Eser Ozturk","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2023080910450959000_50.7.916.28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: A multicenter study from the French uveitis network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"2023080910450959000_50.7.916.29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.sjopt.2016.12.004","article-title":"Successful treatment of Beh\u00e7et\u2019s uveitis with tocilizumab","volume":"31","author":"Alokaily","year":"2017","journal-title":"Saudi J Ophthalmol"},{"key":"2023080910450959000_50.7.916.30","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2023080910450959000_50.7.916.31","doi-asserted-by":"crossref","first-page":"1759720X20971908","DOI":"10.1177\/1759720X20971908","article-title":"Tocilizumab in the treatment of severe and refractory parenchymal neuro-Beh\u00e7et\u2019s syndrome: case series and literature review","volume":"12","author":"Liu","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2023080910450959000_50.7.916.32","first-page":"S73","article-title":"Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report","volume":"30","author":"Urbaniak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2023080910450959000_50.7.916.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.08.004"},{"key":"2023080910450959000_50.7.916.34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neurol.2017.02.006","article-title":"Efficacy and safety of tocilizumab in neuro-Beh\u00e7et\u2019s disease: a case report","volume":"173","author":"Essaadouni","year":"2017","journal-title":"Rev Neurol"},{"key":"2023080910450959000_50.7.916.35","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/rheumatology\/keab840","article-title":"Efficacy and safety of tocilizumab in Beh\u00e7et\u2019s syndrome with refractory arterial lesions: a single-centre observational cohort study in China","volume":"61","author":"Zhong","year":"2022","journal-title":"Rheumatol"},{"key":"2023080910450959000_50.7.916.36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket130"},{"key":"2023080910450959000_50.7.916.37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","article-title":"Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2023080910450959000_50.7.916.38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/biomedicines8050101","article-title":"The role of IL-6 in skin fibrosis and cutaneous wound healing","volume":"8","author":"Johnson","year":"2020","journal-title":"Biomedicines"},{"key":"2023080910450959000_50.7.916.39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/RHU.0000000000000724","article-title":"Successful treatment of amyloid A-type amyloidosis due to Beh\u00e7et disease with tocilizumab","volume":"25","author":"Ilbay","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"2023080910450959000_50.7.916.40","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2013.773913"},{"key":"2023080910450959000_50.7.916.41","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.998198"},{"key":"2023080910450959000_50.7.916.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.07.006"},{"key":"2023080910450959000_50.7.916.43","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1827-x"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.221106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T03:21:30Z","timestamp":1702092090000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.221106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,1]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.3899\/jrheum.221106"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.221106","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}